ANKMJ
Ankyra Medical Journal

Ankyra Medical Journal (AnkMJ), formerly known as the Journal of Translational and Practical Medicine, regularly publishes international quality issues in the field of Medicine in the light of current information.

eISSN: 3023-655X
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
The influence of RANKL/osteoprotegerin on the prognosis of childhood acute lymphoblastic leukemia
Abstract
Aims: The aim is to investigate the association of the osteoprotegerin (OPG)/ soluble(s) receptor activator nuclear kappa B ligand (RANKL) with the prognosis of children with acute lymphoblastic leukemia (ALL).
Methods: Patients with the diagnosis of ALL between the years 2008-2010, were enrolled in the study. Demographic characteristics and complete blood count findings, treatment responses, as well as OPG and sRANKL levels were evaluated on admission and at the end of induction treatment.
Results: Mean serum levels of OPG and sRANKL on admission were 38,6 ±19,03 ng/ml and 0,22±0,24 ng/ml, respectively. Whereas, at the end of induction, serum levels were measured as 35,5±40,8 ng/ml for OPG and 0,033±0,056 ng/ml for sRANKL. A statistically significant decrease was determined for sRANKL at the end of induction therapy, compared to admission (p:0,000).
Conclusion: In the current research, OPG and sRANKL are increased at diagnosis of childhood B-ALL. Whereas, no significant relationship between the OPG and sRANKL levels and the disease prognosis was determined.

Keywords : Acute lymphoblastic leukemia, osteoprotegerin, bone remodeling, prognosis

Download Article


1. Udagawa N, Koide M, Nakamura M, et al. Osteoclastdifferentiation by RANKL and OPG signaling pathways. J BoneMiner Metab. 2021;39(1):19-26. doi:10.1007/s00774-020-01162-6
2. Nakamura M, Udagawa N, Matsuura S, et al. Osteoprotegerinregulates bone formation through a coupling mechanism withbone resorption. Endocrinology. 2003;144(12):5441-5449.doi:10.1210/en.2003-0717
3. Solmaz I, Ozdemir MA, Unal E, Abdurrezzak U, MuhtarogluS, Karakukcu M. Effect of vitamin K2 and vitamin D3 onbone mineral density in children with acute lymphoblasticleukemia: a prospective cohort study. J Pediatr Endocrinol Metab.2021;34(4):441-447. doi:10.1515/jpem-2020-0637
4. Pillai PM, Carroll WL. Acute lymphoblastic leukemia. In:Lanzkowsky 7th Edition. United Kingdom. pp:413-437.
5. İçöz K, Gerçek T, Murat A, Özcan S, Ünal E. Capturing B typeacute lymphoblastic leukemia cells using two types of antibodies.Biotechnol Prog. 2019;35(1):e2737. doi:10.1002/btpr.2737
6. Gök V, Özcan A, Yılmaz E, et al. The significance of solubleCD40 and CD40 ligand levels in childhood acute lymphoblasticleukemia patients. J Transl Pract Med. 2022; 1(2); 49-56.
7. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia inchildren. N Engl J Med. 2015;373(16):1541-1552. doi:10.1056/NEJMra1400972
8. Unal E, Caliskan U, Koksal Y. The importance of cystatin-Cfor predicting nephrotoxicity in children with acute leukemiaand non-Hodgkin lymphoma. UHOD-Uluslararası HematolojiOnkoloji Derg./Int J Hematol Oncol. 2009;19:69-74.
9. Halton J, Gaboury I, Grant R, et al. Advanced vertebral fractureamong newly diagnosed children with acute lymphoblasticleukemia: results of the Canadian Steroid-AssociatedOsteoporosis in the Pediatric Population (STOPP) researchprogram. J Bone Miner Res. 2009;24(7):1326-1334. doi:10.1359/jbmr.090202
10. Alos N, Grant RM, Ramsay T, et al. High incidence of vertebralfractures in children with acute lymphoblastic leukemia12 months after the initiation of therapy. J Clin Oncol.2012;30(22):2760-2767. doi:10.1200/JCO.2011.40.4830
11. Angsubhakorn N, Suvannasankha A. Acute lymphoblasticleukaemia with osteolytic bone lesions: diagnostic dilemma.BMJ Case Rep. 2018;2018:bcr2018225008. doi:10.1136/bcr-2018-225008
12. Nagasawa T. Microenvironmental niches in the bonemarrow required for B-cell development. Nat Rev Immunol.2006;6(2):107-116. doi:10.1038/nri1780
13. Rajakumar SA, Papp E, Lee KK, et al. B cell acute lymphoblasticleukemia cells mediate RANK-RANKL-dependent bonedestruction. Sci Transl Med. 2020;12(561):eaba5942. doi:10.1126/scitranslmed.aba5942
14. Dougall WC. Molecular pathways: osteoclast-dependent andosteoclast-independent roles of the RANKL/RANK/OPGpathway in tumorigenesis and metastasis. Clin Cancer Res.2012;18(2):326-335. doi:10.1158/1078-0432.CCR-10-2507
15. Roodman GD, Dougall WC. RANK ligand as a therapeutic targetfor bone metastases and multiple myeloma. Cancer Treat Rev.2008;34(1):92-101. doi:10.1016/j.ctrv.2007.09.002
16. Rajakumar SA, Danska JS. Bad to the bone: B cell acutelymphoblastic leukemia cells mediate bone destruction. Mol CellOncol. 2020;8(1):1835423. doi:10.1080/23723556.2020.1835423
Article available in :
Volume 2, Issue 1, 2023
Page : 16-19
https://doi.org/10.51271/JTPM-0034
Article Information
Received : 11 Nis 2023
Accepted : 25 Nis 2023
Published : 30 Nis 2023
Corresponding Author :

Ekrem Ünal: Erciyes University, Faculty of Medicine, Department of Pediatrics, Division of Pediatric Hematology & Oncology, Kayseri, Turkey

[email protected]
Citation : Akyol Ş, Özcan A, Yılmaz E, et al. The influence of RANKL/osteoprotegerin on the prognosis of childhood acute lymphoblastic leukemia. J Transl Pract Med. 2023;2(1):17-20.

Read: 342
Cited: 0
Download : 182
_Footer